ADNP (Activity-Dependent Neuroprotective Protein) is a 1,102 amino acid multidomain protein that functions as a transcription factor, chromatin remodeler, and microtubule stabilizer. ADNP is essential for brain development and neuronal survival. The ADNP-derived octapeptide NAP (davunetide/NAPVSIPQ) represents one of the most potent neuroprotective peptides known, acting through microtubule stabilization via end-binding proteins. ADNP directly interacts with tau and protects against tauopathy, connecting it to Alzheimer's disease and related dementias.
[^1]
[^2]
[^3]
[^4]
[^5]
[^6]
[^7]
| Protein Name | Activity-Dependent Neuroprotective Protein |
| Gene | [ADNP](/genes/adnp) |
| UniProt ID | [Q9H2P0](https://www.uniprot.org/uniprot/Q9H2P0) |
| Molecular Weight | ~124 kDa |
| Subcellular Localization | Nucleus, cytoplasm, extracellular |
| Protein Family | Homeobox transcription factors |
| Associated Diseases | [Alzheimer's disease](/diseases/alzheimers-disease), [ADNP syndrome](/diseases/autism), [FTD](/diseases/frontotemporal-dementia) |
ADNP is a large, multidomain protein with several functional regions:
¶ Domain Architecture
- N-terminal region (aa 1–350): Contains the nuclear localization signal and transactivation domain. Interacts with the SWI/SNF chromatin remodeling complex
- Nine zinc fingers (distributed throughout): Mediate DNA binding at specific regulatory elements. Include both C2H2 and C4-type zinc finger motifs
- Homeobox domain (aa 466–525): A 60 amino acid helix-turn-helix motif conferring sequence-specific DNA binding. Recognizes a 5'-ATTA-3' core motif
- PxVxL motif (aa 601–605): Binds the chromoshadow domain of heterochromatin protein 1 (HP1/CBX5), recruiting the BAF chromatin remodeling complex
- NAP motif (aa 354–361, NAPVSIPQ): The neuroprotective octapeptide derived from the SIP domain. Interacts with microtubule end-binding proteins EB1 and EB3
- SH3 domain-binding region: Mediates direct interaction with tau and FYN kinase
- Phosphorylation: Multiple serine/threonine phosphorylation sites regulate nuclear-cytoplasmic shuttling and chromatin binding
- SUMOylation: SUMO modification at Lys-809 modulates transcriptional activity
- Proteolytic processing: ADNP can be cleaved to release bioactive fragments including the NAP peptide
ADNP regulates expression of over 400 genes involved in neuronal development, axon guidance, and synaptic plasticity. Key targets include:
- BDNF and NGF — neurotrophic factor expression
- MAP2 and MAPT — microtubule-associated proteins
- BCL2 — anti-apoptotic signaling
- SLIT1 and ROBO1 — axon guidance molecules
ADNP binds chromatin through its homeobox domain and recruits the BAF complex through HP1-PxVxL interaction, establishing an active chromatin state at target gene promoters.
The NAP motif is critical for ADNP's cytoplasmic function:
- NAP binds EB1 and EB3 at microtubule plus-ends, stabilizing the dynamic instability of growing microtubules
- Promotes microtubule polymerization and prevents depolymerization induced by nocodazole or tau hyperphosphorylation
- Facilitates microtubule invasion into dendritic spines, promoting spine maturation and synaptic stability
- Protects axonal transport by maintaining microtubule tracks for kinesin and dynein motors
ADNP protein is secreted from astrocytes and acts in a paracrine manner to protect neurons:
- Activates MAPK/ERK survival signaling
- Suppresses caspase-3-mediated apoptosis
- Reduces oxidative stress through upregulation of antioxidant enzymes
- Modulates p53 activity to prevent excessive neuronal apoptosis
ADNP directly binds tau through its SH3 domain-binding region:
- Competes with FYN kinase for tau binding at the postsynaptic density
- Prevents tau-mediated excitotoxicity by blocking Fyn-tau-NMDA receptor complex formation
- Protects against tau hyperphosphorylation and missorting
- ADNP deficiency leads to pathological tau accumulation in the somatodendritic compartment
ADNP has a biphasic relationship with AD:
- Early compensatory increase: ADNP expression rises in early AD (MCI/Braak I-II) as a neuroprotective response to amyloid-beta and oxidative stress
- Late-stage decline: In advanced AD (Braak V-VI), ADNP levels drop significantly in hippocampus and cortex, correlating with tau pathology severity
- Serum biomarker: Peripheral ADNP levels (in lymphocytes and serum) are reduced in MCI and AD, potentially serving as an early biomarker
- Tauopathy: ADNP haploinsufficiency in mice produces progressive tauopathy with hyperphosphorylated tau, TDP-43 pathology, and cognitive decline
- Amyloid interaction: NAP peptide protects against amyloid-beta oligomer toxicity in hippocampal neurons
De novo loss-of-function mutations in ADNP cause a neurodevelopmental syndrome featuring:
- Intellectual disability, autism spectrum features, hypotonia
- Most mutations are truncating variants in exon 5 (e.g., p.Tyr719*)
- Truncated proteins lack the C-terminal region including part of the tau-binding domain
- Adult ADNP syndrome patients develop early-onset dementia with mixed tau/TDP-43 pathology
ADNP mutations produce a specific neuropathological pattern resembling FTLD-TDP with comorbid tauopathy, suggesting ADNP dysfunction may contribute to FTD-spectrum disorders.
The ADNP-derived NAP peptide (NAPVSIPQ) is the most advanced therapeutic:
- Mechanism: EB1/EB3 binding, microtubule stabilization, tau protection
- Phase II MCI trial: Intranasal AL-108 improved memory in amnestic MCI patients
- Phase II/III PSP trial: Did not meet primary endpoint in PSP but showed trends in biomarker improvement
- Combinatorial: NAP + SKIP (another ADNP-derived peptide) shows synergistic neuroprotection
AAV-mediated ADNP gene replacement is in preclinical development for ADNP syndrome, showing behavioral rescue in haploinsufficient mice.